Highest-materiality recent filing
Teleflex launches $250M accelerated share repurchase with Truist Bank
ASR with Truist Bank to repurchase $250M of common stock under existing $1B buyback program.
Teleflex Q2 revenue up 4.7% pro forma; cuts revenue guidance, raises adjusted EPS outlook
Q2 revenue $570.3M (+28.9% reported, +4.7% pro forma adj. constant currency); GAAP EPS $0.96, adj. EPS $1.76.
Teleflex completes $1.5B sale of OEM business; pro forma shows debt reduction and improved income
Net cash proceeds of $1.5B ($1.2B after-tax) from OEM business divestiture closed Aug 3, 2026.
Teleflex completes $1.5B sale of OEM business; plans debt paydown and share buybacks
Sale closed Aug 3, 2026 for $1.5B cash to Montagu and Kohlberg.
Teleflex issues $500M of 5.875% senior notes due 2032
$500M aggregate principal of 5.875% senior notes due January 15, 2032; interest paid semi-annually.
Teleflex awards $600K special RSU to Interim CEO Stuart Randle for extended service
Special restricted stock unit award with grant-date fair value of $600,000 to Interim CEO Stuart A. Randle.
Teleflex prices $500M 5.875% senior notes due 2032 to refinance 2027 notes
Priced $500M aggregate principal of 5.875% senior notes due 2032 at 100% of par.
Teleflex announces $500M senior notes offering to refinance 2027 notes
Teleflex commenced offering of $500M senior notes due 2032; proceeds plus cash to redeem all $500M of 4.625% notes due 2027.
Teleflex enters $2.2B new credit facilities; $1B revolver and $1.2B term loans
Entered new $1B revolver, $500M term A-1, and $700M term A-2 credit facilities; refinances prior credit agreement.
Teleflex stockholders re-elect all seven directors and approve say-on-pay at 2026 annual meeting
All seven director nominees received >96% of votes cast (excluding broker non-votes).
Teleflex Q1 revenue up 5.1% pro forma; GAAP EPS $(0.11); maintains FY26 guidance
Revenue from continuing ops $548.3M, up 32.3% reported, +5.1% pro forma adjusted constant currency.
Teleflex appoints Jason Weidman as President and CEO effective June 8, 2026
Weidman succeeds interim CEO Stuart Randle, who remains on the board; Weidman to join board on start date.
Sale transactions of Acute Care, Interventional Urology, and OEM on track for H2 2026 close.
Teleflex updates on OEM and Acute Care divestitures; FTC Second Request for urology deal
OEM HSR waiting period expired March 13, 2026; closing anticipated in Q3 2026.
GAAP revenue from continuing ops $1,992.7M (+17.2% YoY); adjusted revenue $1,983.7M (+16.3%).
Teleflex enters separation agreement with ex-CEO Kelly; transition period through March 2026
CEO Liam Kelly departed Jan 7, 2026; separation agreement signed Jan 23, 2026.
Teleflex CEO Liam Kelly out, interim CEO Stuart Randle appointed; 2025 revenue guide cut
Liam Kelly departs as President and CEO effective Jan 7, 2026; Stuart Randle appointed interim CEO.
Total cash consideration $2.03B: OEM business to Montagu/Kohlberg for $1.5B; Acute Care and Interventional Urology to Intersurgical for $530M.
Teleflex Reports Q3 2025 Revenue Growth but GAAP Loss; Lowers Full-Year Guidance
GAAP revenue $913.0M up 19.4% YoY; adjusted revenue $892.9M up 16.8% (adjusted constant currency up 15.3%).
Teleflex Q2 adj. EPS $3.73 beats $3.42 YoY; raises FY outlook on BIOTRONIK deal
GAAP revenue $780.9M (+4.2% YoY); adjusted constant currency revenue growth +1.0%.
Amendment to Credit Agreement added $200M in delayed draw term loans, bringing total commitments to $700M.
Teleflex amends bylaws to allow stockholder written consent; annual meeting votes pass
Bylaws amended to remove prohibition on stockholder action by written consent, effective May 9, 2025.
Q1 revenue $700.7M (-5.0% reported, -3.8% adj constant currency); GAAP EPS $2.07, adjusted EPS $2.91 (down from $3.21).
Teleflex enters $300M accelerated share repurchase agreement with JPMorgan
Entered $300M ASR with JPMorgan; initial delivery of shares worth 80% of repurchase price based on Feb 27 close.
Teleflex reports Q4 adj EPS $3.89 (+15%); plans two-company split and BIOTRONIK acquisition
Q4 GAAP EPS from cont. ops. $(2.95) vs $0.66; adj EPS $3.89 vs $3.38 (+15.1%). Full-year adj EPS $14.01.
Teleflex Q3 GAAP EPS $2.36, adj $3.49; cuts FY revenue growth guidance to 2.9-3.4%
Q3 GAAP revenue $764.4M, +2.4% YoY; GAAP diluted EPS $2.36 vs $2.91; adjusted diluted EPS $3.49 vs $3.64.
Teleflex CFO adopts 10b5-1 plan for up to 53,754 shares starting Dec 2024
CFO Thomas Powell entered a 10b5-1 trading plan allowing sale of up to 53,754 shares.
Paid $200M to Bank of America on Aug 5, 2024, for initial delivery of shares valued at 80% of repurchase price based on Aug 1 closing price.
Teleflex Q2 adjusted revenue $763.5M (+2.7%); raises FY adj EPS guidance to $13.80-$14.20
GAAP revenue $749.7M (+0.9% YoY); adjusted revenue $763.5M (+2.7% YoY, +3.4% constant currency).
Teleflex CEO Liam Kelly adopts 10b5-1 plan to sell up to 36,464 shares (9% of holdings)
CEO Liam Kelly entered Rule 10b5-1 plan to sell up to 36,464 shares acquired via options expiring 2025; sales in Nov and Dec 2024.
Teleflex Q1 revenue $737.8M (+3.8% YoY); adjusted EPS $3.21 vs $3.09; raises FY adjusted EPS low end
GAAP diluted EPS from continuing ops $0.33 vs $1.63 prior year, reflecting $1.69 pension settlement charge.
Teleflex Reports Q4 2023 Revenue of $773.9M, Full Year Revenue $2,974.5M; Provides 2024 Guidance
Q4 GAAP diluted EPS from continuing operations was $0.66, down from $1.65 in prior year; adjusted EPS was $3.38 vs $3.52.
Teleflex Reports Q3 2023 Revenue of $746.4M, Up 8.7%, Raises Full Year Guidance
Third quarter revenue $746.4M, up 8.7% reported and 7.4% constant currency year-over-year.
Filed DGCL Section 205 petition to validate stockholder votes eliminating supermajority and approving 2023 Stock Incentive Plan.
Teleflex Q2 revenue up 5.9% constant currency; revenue guidance raised, adjusted EPS maintained
Q2 revenues $743.3M, +5.9% constant currency YoY; GAAP diluted EPS $2.35, adjusted diluted EPS $3.41.
Teleflex shareholders approve elimination of supermajority voting provisions
Shareholders voted 41.6M for, 175k against to amend certificate of incorporation, eliminating supermajority voting.
Revenue $710.9M, up 10.8% reported (+13.2% constant currency); growth across all global product categories.
CEO Liam J. Kelly adopts 10b5-1 plan to sell up to 26,256 TFX shares
Plan covers sale of up to 26,256 shares acquired via stock option exercise, ~6.9% of Kelly's total holdings.
Teleflex Q4 2022 revenue $758M, adjusted EPS $3.52; guides 2023 adjusted EPS $13.00-$13.60
Q4 revenue $758.0M (-0.5% reported, +3.7% constant currency); GAAP EPS $1.65, adjusted EPS $3.52.
Teleflex initiates restructuring plan with $31M-$40M charges; expects $21M-$23M annual savings
Initiated 2022 restructuring plan on Nov 15, 2022; substantial completion expected during 2023.
Teleflex amends credit facility: $1B revolver and $500M term loan, maturity Nov 2027
Third Amended and Restated Credit Agreement provides $1.0B revolving and $500M term loan facilities.
Teleflex Q3 revenue down 1.9% YoY; cuts FY 2022 GAAP & adjusted EPS guidance
Q3 revenue $686.8M (-1.9% reported; +2.4% constant currency); GAAP EPS $2.16 vs $4.20 prior.
Revenue $704.5M, down 1.3% YoY; constant currency growth +2.3%.
CEO Liam J. Kelly adopts 10b5-1 plan to sell up to 25,962 shares in Nov-Dec 2022
Plan covers shares from option exercises and represents about 7.5% of Kelly's total holdings.
Reaffirmed 2022 GAAP revenue growth of 2.3%-3.8% (4.0%-5.5% constant currency) and GAAP EPS $8.85-$9.45; adjusted EPS $13.70-$14.30.
Teleflex files 8-K/A to correct typo in 2022 annual meeting vote results
Amendment fixes typographical error in Proposal 5 description from the May 5, 2022 original 8-K.
Teleflex shareholders approve phased-in board declassification starting 2023
A&R Bylaws and Certificate of Incorporation effective May 2, 2022, declassifying board over three years.
Revenue $641.7M, up 1.2% reported (3.2% constant currency); Surgical category grew 14.4% constant currency.
Director Packer to retire at 2022 annual meeting; Neena Patil nominated as independent director
Richard A. Packer will not stand for reelection and will retire from the Board effective immediately before the 2022 annual meeting, due to potential overlap with Asahi Kasei.
Teleflex Q4 revenue $761.9M (+7.1%), adj. EPS $3.60 (+10.8%); 2022 adj. EPS guidance $13.70-$14.30
Q4 reported revenues $761.9M, up 7.1% YoY; constant currency growth 7.9%.
On April 30, 2026, Teleflex Incorporated (the “Company”) announced the appointment of Jason Weidman as the Company’s President and Chief Executive Officer, effective as of June 8, 2026 (the “Start Date”), replacing interim President and Chief Executive Officer Stuart A. Randle at that time.
On April 30, 2026, Teleflex Incorporated (the “Company”) announced the appointment of Jason Weidman as the Company’s President and Chief Executive Officer, effective as of June 8, 2026 (the “Start Date”), replacing interim President and Chief Executive Officer Stuart A. Randle at that time.
who on February 24, 2025 informed the Company that he will retire as Executive Vice President and Chief Financial Officer of the Company, effective April 1, 2025.
the Company’s Board of Directors appointed John R. Deren, 57, who has served as the Company’s Corporate Vice President and Chief Accounting Officer since May 2017, to serve as Executive Vice President and Chief Financial Officer of the Company, effective April 2, 2025.
On February 21, 2022, Richard A. Packer notified the Board of Directors (the "Board") of Teleflex Incorporated ("Teleflex" or the "Company") that he will not stand for reelection to the Board at the Company's 2022 annual meeting of stockholders (the "2022 Annual Meeting") and will retire as a member of the Board, effective immediately prior to the 2022 Annual Meeting.
Max materiality 0.90 · Median 0.62 · Most common event earnings